Cholesterol in remnant-lipoproteins as measured by different methods von Toth, P.P, Bays, H.E, Brown, W.V, Tomassini, J.E, Wang, Y, Polis, A.B, Tershakovec, A.M

Volltext

Ezetimibe does not increase fasting glucose levels more than statins alone in non-diabetic, hypercholesterolemic patients von Toth, P.P, Catapano, A, Farnier, M, Foody, J, Tomassini, J.E, Jensen, E, Polis, A.B, Musliner, T, Tershakovec, A.M

Volltext

Changes in fasting glucose levels following longer-term treatment with simvastatin monotherapy and combined ezetimibe+simvastatin von Toth, P.P, Catapano, A, Farnier, M, Foody, J, Tomassini, J.E, Jensen, E, Polis, A.B, Musliner, T, Tershalovec, A.M

Volltext

Changes in Fasting Glucose Levels Following Longer-Term Treatment with Simvastatin Monotherapy and Combined Ezetimibe+Simvastatin von Toth, Peter P., MD, PhD, Catapano, A., PhD, Farnier, M., MD, PhD, Foody, J., MD, Tomassini, J.E., PhD, Jensen, E., MS, Polis, A.B., MA, Musliner, T., MD, Tershakovec, A.M., MD, MPH

Volltext

Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome von Fazio, S, Guyton, J.R, Lin, J, Tomassini, J.E, Shah, A, Tershakovec, A.M

Volltext

An in vitro Flaviviridae replicase system capable of authentic RNA replication von Tomassini, J.E, Boots, E, Gan, L, Graham, P, Munshi, V, Wolanski, B, Fay, J.F, Getty, K, LaFemina, R

Volltext

Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial von Lee, I.T, Cosgrove, C.A, Moore, P, Bethune, C, Nally, R, Bula, M, Kalra, P.A, Clark, R, Dargan, P.I, Boffito, M, Sheridan, R, Moran, E, Darton, T.C, Burns, F, Saralaya, D, Duncan, C.J.A, Lillie, P.J, San Francisco Ramos, A, Galiza, E.P, Heath, P.T, Girard, B, Parker, C, Rust, D, Mehta, S, de Windt, E, Sutherland, A, Tomassini, J.E, Dutko, F.J, Chalkias, S, Deng, W, Chen, X, Feng, J, Tracy, L, Zhou, H, Miller, J.M, Das, R, Browne, D, Chadwick, D, Emmett, S, Galloway, J, Jones, L, Kaminski, R, Lazarus, R, Palfreeman, A, Ramos, A.S.F, Rampling, T, Sahdev, A, Soiza, R

Volltext bestellen

82 COMBINATION EZETIMIBE/SIMVASTATIN + EXTENDED-RELEASE NIACIN THERAPY IMPROVES ATTAINMENT OF RECOMMENDED LDL-C, NON-HDL-C AND APOB LEVELS IN HYPERLIPIDEMIC PATIENTS von Fazio, S., Guyton, J.R., Lin, J., Tomassini, J.E., Shah, A., Tershakovec, A.M.

Volltext

59 RELATIONSHIPS BETWEEN HSCRP REDUCTION AND LDL-C, NONHDL-C, APOB AND HDL-C IN HYPERLIPIDEMIC PATIENTS TREATED WITH EZETIMIBE/SIMVASTATIN + EXTENDED-RELEASE NIACIN von Brown, W.V., Fazio, S., Guyton, J.R., Dong, Q., Tomassini, J.E., Shah, A., Tershakovec, A.M.

Volltext

MS16 RELATIONSHIPS BETWEEN LDL-C, ApoB AND NON-HDL-C WITH hsCRP IN HYPERCHOLESTEROLEMIC PATIENTS AT RISK FOR CARDIOVASCULAR DISEASE von O'Keefe, J., Abuannadi, M., Lin, J., Shah, A., Neff, D., Tomassini, J.E., Tershakovec, A.

Volltext

80 CHANGES IN LDL-C LEVELS AND GOAL ATTAINMENT ASSOCIATED WITH ADDING EZETIMIBE ONTO SIMVASTATIN, ATORVASTATIN AND ROSUVASTATIN COMPARED WITH TITRATING STATINS von Foody, J.M., Toth, P.P., Sajjan, S., Ramey, D.R., Neff, D.R., Tershakovec, A.M., Hu, H., Tomassini, J.E., Tunceli, K.

Volltext

TIME AND DOSE-RELATED EFFECTS ON THE LIPID PROFILE IN HYPERLIPIDEMIA PATIENTS FOLLOWING TRIPLE COMBINATION THERAPY WITH EZETIMIBE/SIMVASTATIN + NIACIN von Brown, B.G., Fazio, S., Guyton, J.R., Polis, A., Tomassini, J.E., Tershakovec, A.M.

Volltext

SAFETY AND TOLERABILITY OF THE TRIPLE COMBINATION EZETIMIBE/SIMVASTATIN + EXTENDED RELEASE NIACIN IN HYPERLIPIDEMIA PATIENTS von Guyton, J.R., Brown, B.G., Fazio, S., Polis, A., Tomassini, J.E., Tershakovec, A.M.

Volltext

EFFICACY AND SAFETY OF EZETIMIBE/SIMVASTATIN COADMINISTERED WITH EXTENDED RELEASE NIACIN IN PATIENTS WITH TYPE IIA OR IIB HYPERLIPIDEMIA von Fazio, S., Brown, B.G., Guyton, J.R., Polis, A., Tomassini, J.E., Tershakovec, A.M.

Volltext

PO23-786 ASSOCIATION BETWEEN BASELINE LDL-C, TRIGLYCERIDES, AND HDL-C LEVELS AND THE LIPID-ALTERING AND HS-CRP EFFICACIES OF EZETIMIBE/SIMVASTATIN VERSUS ATORVASTATIN IN TYPE 2 DIA... von Goldberg, R.B., Guyton, J.R., Mazzone, T., Weinstock, R.S., Polis, A., Tomassini, J.E., Tershakovec, A.M.

Volltext

PO23-777 EFFECT OF EZETIMIBE/SIMVASTATIN VERSUS ATORVASTATIN ON ATTAINING RECOMMENDED LEVELS OF LDL-C, APOLIOPROTEIN B, NON-HDL-C AND HS-CRP IN TYPE 2 DIABETES von Weinstock, R.S., Goldberg, R.B., Guyton, J.R., Mazzone, T., Polis, A., Tomassini, J.E., Desrosiers, E., Tershakovec, A.M.

Volltext